SEC Form 4 · accession 0001144204-16-137317

Cellectar Biosciences, Inc. · CLRB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Nov 29, 2016

Accepted (ET)

Nov 30, 2016 · 6:59 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001279704

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, par value $0.00001 per share^F1	Nov 29, 2016	P	333,333	$1.49	A	631,317	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series C Warrants (right to buy)^F1	$1.50	Nov 29, 2016	P	333,333	A	Nov 29, 2016	Nov 29, 2021	Common Stock	333,333	607,946	I

F1These securities are held by Venture Investors Early Stage fund IV Limited Partnership and Advantage Capital Wisconsin Partners I, Limited Partnership. VIESF IV GP LLC is the general partner of Venture Investors Early Stage Fund IV Limited Partnership and Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of VIESF IV GP LLC and Venture Investors LLC are made collectively by seven managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein.